NO.1 PHARMACY(SH:600833)2022-04-22 16:00Financial Performance - The company's operating revenue for Q1 2022 was CNY 391,426,974.40, representing an increase of 18.46% compared to the same period last year[5]. - Total operating revenue for Q1 2022 reached CNY 391,426,974.40, an increase of 18.5% compared to CNY 330,419,187.40 in Q1 2021[19]. - Total operating costs for Q1 2022 were CNY 383,410,691.60, up 21.4% from CNY 315,988,245.34 in Q1 2021[19]. - Operating profit for Q1 2022 decreased to CNY 8,150,857.93, down 44.5% from CNY 14,723,522.38 in Q1 2021[19]. - Net profit for Q1 2022 was CNY 8,208,293.96, a decline of 44.5% compared to CNY 14,751,490.81 in Q1 2021[19]. - The net profit attributable to shareholders decreased by 37.74% to CNY 6,258,328.50, primarily due to a lower growth rate in gross profit compared to expense increases[5][8]. - The net profit for Q1 2022 was ¥6,258,328.50, a decrease of 37.6% compared to ¥10,052,516.76 in Q1 2021[20]. - Total comprehensive income for Q1 2022 reached ¥54,842,713.95, significantly up from ¥91,548.74 in Q1 2021[20]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -48,661,494.93, a significant decline of 395.58% year-on-year, impacted by delayed payments from wholesale customers due to the pandemic[5][8]. - Operating cash flow for Q1 2022 was negative at -¥48,661,494.93, compared to a positive cash flow of ¥16,462,872.11 in Q1 2021[21]. - Cash and cash equivalents as of March 31, 2022, were CNY 163,001,907.14, down 37.8% from CNY 262,283,455.11 at the end of 2021[14]. - Cash and cash equivalents at the end of Q1 2022 were ¥151,071,135.14, down from ¥332,076,819.77 at the end of Q1 2021[22]. - The company incurred total operating cash outflows of ¥459,202,592.89 in Q1 2022, compared to ¥358,220,582.93 in Q1 2021[21]. - Investment activities resulted in a net cash outflow of -¥42,102,569.55 in Q1 2022, compared to -¥4,575,061.81 in Q1 2021[22]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 31,143[10]. - The largest shareholder, Bailian Group Co., Ltd., holds 44.95% of the shares, totaling 100,274,734 shares[11]. - Shareholders' equity attributable to the parent company increased by 7.11% to CNY 825,758,971.80[6]. - Shareholders' equity increased to CNY 832,766,287.69 from CNY 777,923,573.74, an increase of 7.0%[16]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,353,150,015.44, an increase of 1.40% from the end of the previous year[6]. - Total assets as of March 31, 2022, were CNY 1,353,150,015.44, a slight increase from CNY 1,334,462,955.15 at the end of 2021[16]. - Total liabilities decreased to CNY 520,383,727.75 from CNY 556,539,381.41, a reduction of 6.5%[16]. - Accounts receivable decreased to CNY 122,699,748.29 from CNY 133,558,538.35, a reduction of 8.3%[14]. - Inventory increased to CNY 236,684,345.59, up 10.4% from CNY 214,496,533.27 at the end of 2021[14]. Earnings Per Share - Basic and diluted earnings per share both decreased by 37.69% to CNY 0.0281[6][8]. - The basic and diluted earnings per share for Q1 2022 were both ¥0.0281, down from ¥0.0451 in Q1 2021[20]. Government Subsidies - The company received government subsidies amounting to CNY 134,575.13, which are closely related to its normal business operations[7]. Other Comprehensive Income - The company reported a decrease in other comprehensive income, with a net amount of ¥48,584,385.45 in Q1 2022, compared to a loss of -¥9,960,968.02 in Q1 2021[20]. Return on Equity - The weighted average return on equity fell to 0.78%, a decrease of 0.58 percentage points compared to the previous year[6].